Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29765332
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 251.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29765332
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Front+Physiol
2018 ; 9
(ä): 452
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A
Systematic Review and Meta-Analysis
#MMPMID29765332
Zhou X
; Sun L
; Jing D
; Xu G
; Zhang J
; Lin L
; Zhao J
; Yao Z
; Lin H
Front Physiol
2018[]; 9
(ä): 452
PMID29765332
show ga
Background and Objective: Galectin-9 (Gal-9) is one of the galectin family
members which are known as proteins with ?-galactoside-binding affinity.
Accumulative evidence suggest that Gal-9 plays multifaceted roles in tumor
biology. However, the prognostic significance of Gal-9 in solid cancer patients
remains controversial. The objective of the study was to clarify the prognostic
significance of Gal-9 in solid tumors via meta-analysis. Methods: We searched
PubMed, Embase and the Cochrane library for studies that report the correlation
between Gal-9 expression and prognosis or clinicopathological parameters in solid
cancer patients from inception to October 2017, with no language restriction. We
calculated pooled hazard ratio (HR) and 95% confidence interval (CI) to
investigate the prognostic significance of Gal-9 expression in solid tumors. We
also calculated Odds ratio (OR) to explore the association between Gal-9
expression and clinicopathological features. Results: We included Fourteen
studies with 2326 patients in our meta-analysis. The synthetic results revealed
that high Gal-9 expression indicated improved overall survival (OS; HR = 0.70,
95% CI = 0.51-0.71, P = 0.006) but had no correlation with disease-free survival
(DFS)/recurrence-free survival (RFS) (HR = 0.85, 95% CI = 0.51-1.41, P = 0.527)
in solid tumors. In stratified analyses, high Gal-9 expression was significantly
correlated with improved OS in hepatocellular carcinoma and colon cancer and with
improved DFS/RFS in gastric cancer and non-small cell lung cancer. In addition,
ethnicity and the method of data extraction didn't affect the positive prognostic
values of high Gal-9 expression. Moreover, high Gal-9 expression was
significantly correlated with a smaller depth of invasion (TI/TII vs. TIII/TIV,
OR = 2.80, 95% CI = 1.97-3.96, P < 0.001), an earlier histopathological stage
(I/II vs. III/IV, OR = 3.00, 95% CI = 2.04-4.42, P < 0.001), negative lymph node
metastasis (Presence vs. Absence, OR = 0.47, 95% CI = 0.25-0.89, P = 0.020) and
negative distal tumor metastasis (Presence vs. Absence, OR = 13.85, 95% CI =
3.50-54.76, P < 0.001). Conclusion: Gal-9 expression indicates beneficial outcome
in patients with solid tumors and is correlated with the pathogenesis of solid
tumors. Gal-9 may serve as a prognostic biomarker and an emerging therapeutic
target against solid tumors.